Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study

By afschroeder • June 5, 2025

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003699. Epub ahead of print. PMID: 40465394.

Tags: Humanized IgG4 monoclonal antibody, Ibalizumab, Infectious Diseases, Multidrug-resistant human immunodeficiency virus type 1, Optimized background regimen, Publications, Viral entry inhibitor

Non-viable Aspergillus fumigatus promotes chronic inflammation and angiogenesis in a murine fungus ball model

Hamashima R, Tashiro M, Nakano Y, Shirahige T, Namie H, Yano H, Ito Y, Yoshida M, Hirayama T, Takeda K, Iwanaga N, Kakiuchi S, Nishi[...]

Doxycycline-Induced Phototoxicity Localized to Vitiligo-Affected and Sun-Exposed Skin

Dong S, Harris C, Ly A, Lee PS. Doxycycline-Induced Phototoxicity Localized to Vitiligo-Affected and Sun-Exposed Skin. Cureus. 2026 Feb 17;18(2):e103789. doi: 10.7759/cureus.103789. PMID: 41869147; PMCID:[...]

“It’s being uncomfortable for who you are, because I think HIV is part of me … “: psychosocial adaptation and treatment engagement among GBMSM older and younger than 30 years engaged in a coping and disclosure skills intervention in the Eastern Cape, South Africa

de Vos L, Rutt K, Metula A, Peters RPH, Bongo C, Daniels J. "It's being uncomfortable for who you are, because I think HIV is[...]